Summary
The effect of calcium dobesilate on the alteration of the blood-retinal barrier was studied in 41 adult-onset, non-insulin dependent diabetic patients with minimal or no retinopathy, randomly assigned to receive either oral calcium dobesilate (1000 mg twice daily) or a placebo for 12 months. The posterior vitreous value and the penetration ratio, determined by vitreous fluorophotometry, reflected stabilisation of blood-retinal barrier permeability in the calcium dobesilate patients and deterioration of blood retinal barrier in those given placebo. During the relatively short period of the study, one year, no significant change in microaneurysm and capillary closure gradings was observed. No side effects were associated with calcium dobesilate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bussolino F, Biffignandi P, Arese P. Platelet-Activating factor. A powerful lipid autacoid: Possibly involved in microangiopathy. Acta Haematologica 1986; 75(3): 129–40.
Cunha-Vaz JG. Pathophysiology of diabetic retinopathy. Br J Ophthalmol 1978; 62: 351–5.
Cunha-Vaz JG, Abreu JR, Campos AJ, Figo G. Early breakdown of the blood retinal barrier in diabetes. Br J Ophthalmol 1975; 59: 649–56.
Cunha-Vaz JG, Gray JR, Zeimer RC, Mota MC, Ishimoto BH, Leite EB. Characterization of the early stages of diabetic retinopathy by vitreous fluorophotometry. Diabetes 1985; 34: 53–9.
Cunha-Vaz JG, Mota MC, Leite EB, Abreu JR, Ruas MA. Effect of sulindac on the permeability of the Blood-Retinal Barrier in early diabetic retinopathy. Arch Ophthalmol 1985; 103: 1307–11.
Cunha-Vaz JG, Mota MC, Leite EB, Abreu JR, Ruas MA. Effect of sorbinil on Blood-Retinal Barrier in early diabetic retinopathy. Diabetes 1986; 35(5): 574–8.
Diabetic Retinopathy Study Research Group: Report 7: A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci 1981; 21: 210–6.
Falkay G, Kovacs L. Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro. Experientia 1984; 40: 190–1.
Freyler H. Microvascular protection with calcium dobesilate (Doxium) in diabetic retinopathy. Ophthalmologica 1974; 168: 400–16.
Gloviczki P, Fowl RJ, Hollier LH, Dewanjee MK, Plate G, Kaye MP. Prevention of platelet deposition by ibuprofen and calcium dobesilate in expanded polytetrafluoroethylene vascular grafts. Am J Surg 1985; 150: 589–92.
Salama BI, Brodsky M, Rubenstein A, Viggiano C, Salama EA. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Research 1985; 17: 131–8.
Schmidt M, Michal M. Inhibits of sorbitol formation in human erythrocytes by calcium dobesilate. Drug Res 1989; 4.
Sevin R, Cuendet JF. The action of calcium dobesilate on capillary permeability in diabetics. Ophthalmologica 1971; 162: 33–40.
Sinzinger H, Rauscha F, Vinazzer H. Platelet function and prostaglandins in patients with peripheral vascular disease treated with calcium dobesilate. Prostaglandins, Leukotrienes and Medicine 1987; 29: 1–9.
Smith RT, Lee CM, Charles HC, Cunha-Vaz JG. Quantification of diabetic macular edema. Arch Ophthalmol 1987; 105: 218–22.
Van Bijsterveld OP, Janssen PT. Conservative therapy of diabetic retinopathy. Symposium on diabetic retinopathy. Cannes 1984. Schattauer, Stuttgart, 1984.
Vinazzer H, Hachen HJ. Influence of calcium dobesilate (Doxium) on blood viscosity and coagulation parameters in diabetic retinopathy. VASA 1987; 16: 190–2.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leite, E.B., Mota, M.C., de Abreu, J.R.F. et al. Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol 14, 81–88 (1990). https://doi.org/10.1007/BF00154206
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00154206